| 0.22 0 (0%) | 02-14 15:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.34 | 1-year : | 0.44 |
| Resists | First : | 0.29 | Second : | 0.38 |
| Pivot price | 0.21 | |||
| Supports | First : | 0.15 | Second : | 0.12 |
| MAs | MA(5) : | 0.21 | MA(20) : | 0.21 |
| MA(100) : | 2.16  |
MA(250) : | 5.44 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 30.4 | D(3) : | 30.4 |
| RSI | RSI(14): 17 | |||
| 52-week | High : | 19.89 | Low : | 0.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BIOR ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.38 - 0.38 | 0.38 - 0.38 |
| Low: | 0.15 - 0.15 | 0.15 - 0.15 |
| Close: | 0.22 - 0.22 | 0.22 - 0.22 |
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Tue, 10 Dec 2024
Biora Therapeutics to be delisted from Nasdaq - Investing.com
Tue, 10 Dec 2024
Why Biora Therapeutics (BIOR) Stock Is Down 45% - Benzinga
Thu, 14 Nov 2024
Biora Therapeutics Inc (BIOR) Quarterly 10-Q Report - Quartz
Thu, 14 Nov 2024
Biora Therapeutics Advances BioJet Device, Cuts Monthly Expenses 40% Amid Q3 Loss - StockTitan
Wed, 13 Nov 2024
Biora Therapeutics Inc (BIOR) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Tue, 29 Oct 2024
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 36 (%) |
| Shares Short | 290 (K) |
| Shares Short P.Month | 202 (K) |
| EPS | 0.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -36.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0.61 |
| PEG Ratio | 0 |
| Price to Book value | -0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|